Avmacol ES for Heart Failure, Diastolic

Phase-Based Progress Estimates
Texas Tech University Health Sciences Center (TTUHSC), Lubbock, TX
Heart Failure, Diastolic+2 More
Sulforaphane - Drug
All Sexes
What conditions do you have?

Study Summary

Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral blood cells from treated and control subjects will be compared for mitochondrial respiratory function, oxidative damage, pro-inflammatory cytokines, and expression of antioxidant & anti-electrophile genes.

Eligible Conditions

  • Heart Failure, Diastolic
  • Systolic Dysfunction
  • Diastolic Dysfunction

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Heart Failure, Diastolic

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: 24 week

24 week
Functional Capacity
Hand grip test
Muscle Function
cardiac function
24 weeks
DNA damage, CBC, Oxidative stress

Trial Safety

Safety Progress

1 of 3

Other trials for Heart Failure, Diastolic

Trial Design

2 Treatment Groups

Avmacol ES
1 of 2
1 of 2
Active Control
Non-Treatment Group

200 Total Participants · 2 Treatment Groups

Primary Treatment: Avmacol ES · Has Placebo Group · Phase 1 & 2

Avmacol ES
ActiveComparator Group · 1 Intervention: Sulforaphane · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Sulforaphane · Intervention Types: Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 week
Closest Location: Texas Tech University Health Sciences Center (TTUHSC) · Lubbock, TX
Photo of texas 1Photo of texas 2Photo of texas 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Heart Failure, Diastolic
0 CompletedClinical Trials

Who is running the clinical trial?

Texas Tech University Health Sciences CenterLead Sponsor
97 Previous Clinical Trials
9,709 Total Patients Enrolled
1 Trials studying Heart Failure, Diastolic

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You can walk more than 500 feet (by self-report).
You have HFpEF (HF symptoms with a normal EF (>/=50 %)).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.